The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...
MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...
The pharma giant said its weight loss medication helped patients living with obesity or who are overweight ... after 68 weeks ...